Slide 1: Thyrocare - Think Thyroid. Think Thyrocare.
Thyrocare· Think Thyroid. Think Thyrocare. August 12, 2019 The National Stock Exchange of India Limited The Bombay Stock Exchange Ltd Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 00 I Dear Sirs, Sub: Presentation on Quarterly Re
Slide 2: Disclaimer
Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, informatio
Slide 3: Highlights - Financial Performance - Thyrocare
Highlights - Financial Performance - Thyrocare Revenue Revenue from operations Q1-20 - Rs. 100.50 crore (+13%) growth [Q1-19 - Rs. 89.19 crore] 13% QYOY Samples processed Q1-20 – 50.01 lakhs (+9%) [Q1-19 – Samples 45.80 lakhs] growth 9% QYOY Investigations performed Q1-20 – 283.4 lakhs (+18%) [Q1- I
Slide 4: Highlights - Financial Performance - Thyrocare (Continued)
Highlights - Financial Performance – Thyrocare (Continued..) Cost of reagents & consumables Cost of reagents and consumables maintained at 29% of topline. Employee benefits expense EBITDA Q1-20- Rs. 43.70 crore (EBITDA margin 44 %) [Q1-19 - Employee benefit expenses cost increased Rs. 39.11 crore ]
Slide 5: Highlights - Operational Performance - Pathology
Highlights - Operational Performance - Pathology Q1 Revenue by nature Q1 Revenue by type Wellness Value Q1-20 - Rs. 48.7 crore (52%) [Q1-19- Rs. 41.2 crore 21% (49%)] - Wellness Volume Q1-20 – 6.9 lakhs (14% of total samples) [Q1-19 – 48% 52% 5.5 lakhs (12% of total samples)] 79% B2B Value Q1-20 - R
Slide 6: Highlights - MCGM - Aapli Chikitsa
Highlights - MCGM – Aapli Chikitsa Outsourcing of laboratory investigations by MCGM Contract for 4 years totaling to Rs. 52 crore Assured revenue of 60% throughout terms Services to Western suburbs and city Covering 13 hospitals, 159 dispensaries/ clinics Rolled out operations at functioning locatio
Slide 7: Highlights - NIPT/NGS
Highlights – NIPT/ NGS An early prenatal genetic screening test Rolled out operations in May 2019 Launched at 50 % of the Market Price. Huge potential with rising income level, health awareness and government initiatives.
Slide 8: Highlights - Financial Performance - Nueclear
Highlights - Financial Performance - Nueclear Revenue from operations Q1-20 - Rs. 9.47 crore (+19%) [Q1-19 - Rs. 7.96 crore] - Revenue from imaging services Q1-20 - Rs. 8.71 crore (+17%) [Q1-19 - Rs. 7.47 crore] - Revenue from sale of FDG Q1-20 - Rs. 0.76 crore (+52%) [Q1-19 - Rs. 0.50 crore] Scans
Slide 9: Highlights - Financial Performance - Nueclear
Highlights - Financial Performance - Nueclear Cost of FDG & consumables Cost of FDG and consumables remained at 14% of topline. EBITDA Q1-20 - Rs. 1.31 crore (EBITDA margin 14 %) [Q1-19 - In Gujarat we have started sourcing FDG from Rs. 1.78 crore (22%)] partnered vendor. Employee benefits expense E
Slide 10: Highlights - Financial Performance - Consolidated
Highlights - Financial Performance - Consolidated Revenue growth Revenue from operations Q1-20 - Rs. 109.73 crore (+13%) 13% QYOY [Q1-19 - Rs. 97.15 crore] EBITDA Q1-20 - Rs. 45.61 crore (EBITDA margin 42 %) [Q1- Consolidated EBITDA 19 - Rs. 41.24 crore (42%)] margin 42% PAT Q1-20 - Rs. 27.47 crore
Slide 11: Adoption of Ind AS 116 Leases
Adoption of Ind AS- 116 “Leases” The Company has adopted Indian Accounting Standard 116 - Leases ("Standard"), with effect from 1 April 2019 using the modified retrospective method under the transitional provisions of the Standard and has taken the cumulative adjustment to retained earnings as on 1
Slide 12: Thank You
thank You